Previous 10 | Next 10 |
home / stock / abbv / abbv articles
This week, an FDA advisory committee unanimously recommended approval of Eli Lilly's (NYSE: LLY) Alzheimer's disease drug, donanemab. Pfize...
In today's fast-paced and highly competitive business world, it is crucial for investors and industry followers to conduct comprehensive compa...
AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.41% on an annualized basis producing an average annual return of 12.01%....
AbbVie Inc’s (NYSE:ABBV) top-selling arthritis drug, Humira, has managed to retain over 80% of its patients even after facing nine lower-pric...
On CNBC's “Halftime Report Final Trades,” Jim Lebenthal of Cerity Partners said AbbVie Inc. (NYSE:ABBV) is a very solid pharmaceut...
Halozyme Therapeutics (NASDAQ: HALO) announced that it has been granted a new patent in the EU that covers the ENHANZE rHuPH20 product, which ...
On Thursday, AbbVie Inc (NYSE:ABBV) released topline results from the Phase 2 PICCOLO trial evaluating investigational mirvetuximab soravtansi...
AbbVie (NYSE: ABBV) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has a...
On CNBC's “Halftime Report Final Trades,” Brenda Vingiello of Sand Hill Global Advisors named The TJX Companies, Inc. (NYSE:TJX) a...
News, Short Squeeze, Breakout and More Instantly...
2024-07-17 08:25:00 ET Stocks that are trading at low- and discounted-earnings multiples can sometimes be value traps. But other times, it's just due to short-term and temporary factors that the stocks aren't doing terribly well. In these situations, there are opportunities for investors to...
2024-07-14 04:27:00 ET The broader stock market benchmarks keep reaching new heights, but the S&P 500 index's ongoing bull run has been driven heavily by its largest components. That means there are still plenty of reliable dividend-paying stocks that look like bargains. Shares ...
AbbVie Submits Regulatory Applications to FDA and EMA for Upadacitinib (RINVOQ®) in Giant Cell Arteritis PR Newswire Submissions are supported by the Phase 3 SELECT-GCA study demonstrating upadacitinib 15 mg with a 26-week steroid taper regimen achieved the primary endp...